AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26610166 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25
Study 26610166 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone treatment
Number of subjects: 25
Study 26610166 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone treatment with secretagogues (PGE2, theophylline, ouabain)
Number of subjects: 25
Study 26610166 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine application
Number of subjects: 25
Study 24034178 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen dive
Number of subjects: 26
Study 24034178 — intervention group
Group type: COMPARATOR
Intervention: Compressed air dive
Number of subjects: 26
Study 22172434 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase plus heparin
Number of subjects: 1000
Study 22172434 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 1000
Study 20858697 — intervention group
Group type: EXPERIMENTAL
Intervention: SET plus hypocaloric diet for 6 weeks (Group C)
Number of subjects: 96
Study 20858697 — intervention group
Group type: COMPARATOR
Intervention: SET plus hypocaloric diet for 6 weeks (Group A)
Number of subjects: 96
Study 20858697 — intervention group
Group type: COMPARATOR
Intervention: 2 weeks of observation followed by one cycle of CC therapy (Group B)
Number of subjects: 96
Study 20858697 — intervention group
Group type: EXPERIMENTAL
Intervention: SET plus hypocaloric diet for 6 weeks (Groups A and C)
Number of subjects: 96
Study 18954289 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric scooter simulation intervention group
Number of subjects: 10
Study 18954289 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 16822627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention group (IG) with biweekly nutrition education and low-fat, fortified dairy products
Number of subjects: 82
Study 16822627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention group (IG)
Number of subjects: 82
Study 12930613 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (200 mg three times daily for 3 days)
Number of subjects: 146
Study 12930613 — intervention group
Group type: EXPERIMENTAL
Intervention: Secnidazole (30 mg/kg, in a single dose)
Number of subjects: 146
Study 10807711 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial bilayer membrane grafted in 8 patients
Number of subjects: 13
Study 10807711 — intervention group
Group type: COMPARATOR
Intervention: Standard closure by suture in 5 patients (control group)
Number of subjects: 13
Study 8656366 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mm incision (Group A)
Number of subjects: 58
Study 8656366 — intervention group
Group type: COMPARATOR
Intervention: 5.0 mm incision (Group B)
Number of subjects: 58
Study 8656366 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 58
Study 1458765 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2mg moxonidine twice daily
Number of subjects: 15
Study 1458765 — intervention group
Group type: COMPARATOR
Intervention: 0.2mg digoxin once daily
Number of subjects: 15
Study 3881122 — intervention group
Group type: EXPERIMENTAL
Intervention: External cephalic version attempted in 310 patients
Number of subjects: 640
Study 3881122 — intervention group
Group type: COMPARATOR
Intervention: Control group (330 patients, version not attempted)
Number of subjects: 640
Study 29743128 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 only
Number of subjects: 282
Study 29743128 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 + social skills
Number of subjects: 282
Study 29743128 — intervention group
Group type: EXPERIMENTAL
Intervention: social skills only
Number of subjects: 282
Study 29743128 — intervention group
Group type: COMPARATOR
Intervention: placebo control
Number of subjects: 282
Study 27997679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir (90 mg ledipasvir and 400 mg sofosbuvir once daily for 12 weeks)
Number of subjects: 100
Study 26345320 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth Readiness Intervention (YRI)
Number of subjects: 436
Study 26345320 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 436
Study 25054452 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (3.0 g/day of EPA and DHA)
Number of subjects: 30
Study 25054452 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 30
Study 25054452 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 30
Study 22243363 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 8586
Study 22243363 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based treatment
Number of subjects: 8586
Study 22243363 — intervention group
Group type: EXPERIMENTAL
Intervention: In-treatment serum K ≤ 3.90
Number of subjects: 8586
Study 19544230 — intervention group
Group type: COMPARATOR
Intervention: Modified Menghini-type needle (MMT)
Number of subjects: 307
Study 19544230 — intervention group
Group type: EXPERIMENTAL
Intervention: Tru-cut-type needle (TCT)
Number of subjects: 307
Study 19544230 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cytology and histology
Number of subjects: 307
Study 17947724 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1614
Study 17947724 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 1614
Study 17947724 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1614
Study 14872275 — intervention group
Group type: EXPERIMENTAL
Intervention: CISS (Constructive Interference in Steady State)
Number of subjects: 101
Study 14872275 — intervention group
Group type: EXPERIMENTAL
Intervention: True-FISP (True Fast Imaging in Steady State Precession)
Number of subjects: 101
Study 14872275 — intervention group
Group type: EXPERIMENTAL
Intervention: T1-weighted spin-echo (T1SE)
Number of subjects: 101
Study 14872275 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver analysis
Number of subjects: 101
Study 14872275 — intervention group
Group type: COMPARATOR
Intervention: Chest Radiography (CR)
Number of subjects: 101
Study 11878178 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy with technical accessories and splints
Number of subjects: 33
Study 9747912 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine (1-2 mg/day)
Number of subjects: 73
Study 9747912 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (40 mg/day)
Number of subjects: 73
Study 8155207 — intervention group
Group type: EXPERIMENTAL
Intervention: Curosurf (natural surfactant)
Number of subjects: 42
Study 8155207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 3076795 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa (750 mg daily)
Number of subjects: 25
Study 3076795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 30024488 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral lower leg heating (LLH) via water bath immersion at 42°C for 15 minutes
Number of subjects: 6
Study 30024488 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral lower leg heating (LLH) via water bath immersion at 42°C for 45 minutes
Number of subjects: 6
Study 30024488 — intervention group
Group type: COMPARATOR
Intervention: Control (no heating)
Number of subjects: 6
Study 28258828 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA-TGN concentration during maintenance therapy
Number of subjects: 918
Study 28258828 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte concentrations of TGN, methylated mercaptopurine metabolites, and methotrexate polyglutamates
Number of subjects: 918
Study 25881117 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 44
Study 25881117 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 44
Study 24390682 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory before simulation
Number of subjects: 20
Study 24390682 — intervention group
Group type: COMPARATOR
Intervention: Simulation before theory
Number of subjects: 20
Study 23041713 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical acupoint stimulation (EAS) at maximal intensity without pain
Number of subjects: 40
Study 23041713 — intervention group
Group type: COMPARATOR
Intervention: Minimal-EAS at a just detectable intensity
Number of subjects: 40
Study 23041713 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between EAS and minimal-EAS
Number of subjects: 40
Study 19503783 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 150 mg once a month
Number of subjects: 0
Study 17718644 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling of trigger points and paraspinal needling
Number of subjects: 40
Study 17718644 — intervention group
Group type: COMPARATOR
Intervention: Dry needling of trigger points only
Number of subjects: 40
Study 17718644 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 15186934 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (150-200 microg/kg body weight)
Number of subjects: 1829
Study 15186934 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (150-200 microg/kg body weight) + Albendazole (400 mg)
Number of subjects: 1829
Study 15186934 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1829
Study 15186934 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 1829
Study 11753309 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of bias at entry
Number of subjects: 62
Study 11753309 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of bias in assessment of outcome
Number of subjects: 62
Study 11753309 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of bias after entry
Number of subjects: 62
Study 11753309 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall quality scores
Number of subjects: 62
Study 11753309 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of randomization
Number of subjects: 62
Study 9667292 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine (0.15, 0.30, or 0.60 microg/ml)
Number of subjects: 30
Study 9667292 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (0.1, 0.15, or 0.2 ng/ml)
Number of subjects: 30
Study 9075462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal protirelin (500 micrograms)
Number of subjects: 8
Study 9075462 — intervention group
Group type: COMPARATOR
Intervention: Sham lumbar puncture procedure
Number of subjects: 8
Study 2117932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound scanning within 48 hours of injury
Number of subjects: 114
Study 2117932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound scanning
Number of subjects: 114
Study 6783707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential study (6 persons subinoculated with malaria-rich blood)
Number of subjects: 21
Study 6783707 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective study (15 volunteers receiving malaria-rich blood from 14 different donors)
Number of subjects: 21
Study 6783707 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings from both studies
Number of subjects: 21
Study 6783707 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 21
Study 31558345 — intervention group
Group type: EXPERIMENTAL
Intervention: Reticular pseudodrusen (RPD) presence
Number of subjects: 2516
Study 28180985 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 9
Study 28180985 — intervention group
Group type: COMPARATOR
Intervention: ACV
Number of subjects: 9
Study 26551196 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine with alcohol
Number of subjects: 1404
Study 26551196 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine with alcohol
Number of subjects: 1404
Study 26551196 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential combination of both solutions
Number of subjects: 1404
Study 26551196 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1404
Study 25886386 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragaloside IV (AS-IV) treatment
Number of subjects: 4
Study 25886386 — intervention group
Group type: COMPARATOR
Intervention: 4-phenyl butyric acid (PBA) treatment
Number of subjects: 4
Study 25886386 — intervention group
Group type: COMPARATOR
Intervention: Normal control (Normal group)
Number of subjects: 4
Study 25886386 — intervention group
Group type: COMPARATOR
Intervention: Diabetic nephropathy (Model group)
Number of subjects: 4
Study 24014917 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin medication (Group-I)
Number of subjects: 30
Study 24014917 — intervention group
Group type: COMPARATOR
Intervention: No statin medication (Group-II)
Number of subjects: 30
Study 21922033 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary rewards during approach sessions
Number of subjects: 0
Study 21922033 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoid monetary losses during avoidance sessions
Number of subjects: 0
Study 21922033 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative reinforcer presence
Number of subjects: 0
Study 19748656 — intervention group
Group type: EXPERIMENTAL
Intervention: laropiprant 300 mg/d for 3 weeks
Number of subjects: 867
Study 19748656 — intervention group
Group type: EXPERIMENTAL
Intervention: laropiprant plus montelukast 10 mg/d for 2 weeks
Number of subjects: 867
Study 19748656 — intervention group
Group type: COMPARATOR
Intervention: montelukast
Number of subjects: 867
Study 19748656 — intervention group
Group type: EXPERIMENTAL
Intervention: laropiprant 25 mg/d or 100 mg/d
Number of subjects: 867
Study 19748656 — intervention group
Group type: COMPARATOR
Intervention: cetirizine 10 mg/d
Number of subjects: 867
Study 19748656 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 867
Study 16522757 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-based seminar with a behavioral science instructor
Number of subjects: 204
Study 16522757 — intervention group
Group type: COMPARATOR
Intervention: Case-based seminar without a behavioral science instructor
Number of subjects: 204
Study 14701888 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach visits (EOVs)
Number of subjects: 0
Study 14701888 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailout strategies
Number of subjects: 0
Study 14701888 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 11045796 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 grams of ground flaxseed per day
Number of subjects: 31
Study 11045796 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 grams of ground flaxseed per day
Number of subjects: 31
Study 11045796 — intervention group
Group type: COMPARATOR
Intervention: 0 grams of ground flaxseed per day
Number of subjects: 31
Study 10099062 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide plus labetalol
Number of subjects: 11
Study 10099062 — intervention group
Group type: COMPARATOR
Intervention: Labetalol alone
Number of subjects: 11
Study 10099062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 10099062 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 11
Study 7976777 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornithine oxoglutarate (OGO)
Number of subjects: 194
Study 7976777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 2700991 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-green argon laser
Number of subjects: 20
Study 2700991 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochromatic green argon laser
Number of subjects: 20
Study 2700991 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow dye laser
Number of subjects: 20
Study 2700991 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 1146928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethynylestradiol or mestranol (50 to 100 mug per day)
Number of subjects: 191
Study 1146928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethynylestradiol or mestranol with 2.5 mg norethindrone acetate, 2 mg megestrol acetate, or 0.5 mg norgestrel
Number of subjects: 191
Study 1146928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethynylestradiol or mestranol (various doses)
Number of subjects: 191
Study 1146928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethynylestradiol or mestranol with progestational agent
Number of subjects: 191
Study 1146928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethynylestradiol (50 mug per day)
Number of subjects: 191
Study 1146928 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oral contraceptives
Number of subjects: 191
Study 1146928 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen agents (50 to 75 mug per day)
Number of subjects: 191
Study 1146928 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (IUD cycles) and chronic treatment with oral contraceptives
Number of subjects: 191
Study 31332029 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 IU b.i.d. plus pioglitazone 45 mg/day
Number of subjects: 105
Study 31332029 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 IU b.i.d.
Number of subjects: 105
Study 31332029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 29231585 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus western medicine
Number of subjects: 76
Study 29231585 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 76
Study 29231585 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups after treatment
Number of subjects: 76
Study 26672701 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized plastic shield on brackets
Number of subjects: 42
Study 26672701 — intervention group
Group type: COMPARATOR
Intervention: No shield on brackets
Number of subjects: 42
Study 24858769 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) for three menstrual cycles
Number of subjects: 78
Study 24858769 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) for more than three cycles
Number of subjects: 78
Study 24858769 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 78
Study 24858769 — intervention group
Group type: COMPARATOR
Intervention: Control group (women who never used ovulation drugs)
Number of subjects: 78
Study 21257986 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (600 IU every other day)
Number of subjects: 38597
Study 21257986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38597
Study 18990503 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 Gy in 40 fractions within 8 weeks (Group A)
Number of subjects: 212
Study 18990503 — intervention group
Group type: EXPERIMENTAL
Intervention: 62 Gy in 20 fractions within 5 weeks (Group B)
Number of subjects: 212
Study 18990503 — intervention group
Group type: EXPERIMENTAL
Intervention: 56 Gy in 16 fractions (4/wk) of 3.5 Gy (Group C)
Number of subjects: 212
Study 16850002 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral diet enriched with eicosapentaenoic acid (EPA), gamma-linolenic acid (GLA), and antioxidants
Number of subjects: 165
Study 16850002 — intervention group
Group type: COMPARATOR
Intervention: Control diet (isonitrogenous and isocaloric)
Number of subjects: 165
Study 16850002 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral diet enriched with EPA, GLA, and antioxidants
Number of subjects: 165
Study 12605431 — intervention group
Group type: EXPERIMENTAL
Intervention: Low power laser therapy + exercise
Number of subjects: 75
Study 12605431 — intervention group
Group type: EXPERIMENTAL
Intervention: Low power laser therapy alone
Number of subjects: 75
Study 12605431 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise alone
Number of subjects: 75
Study 10670908 — intervention group
Group type: EXPERIMENTAL
Intervention: manidipine hydrochloride
Number of subjects: 39
Study 10670908 — intervention group
Group type: COMPARATOR
Intervention: delapril hydrochloride
Number of subjects: 39
Study 9356536 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (100 mg elemental Fe/d)
Number of subjects: 197
Study 9356536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 10155247 — intervention group
Group type: EXPERIMENTAL
Intervention: 6Fr guiding catheter
Number of subjects: 160
Study 10155247 — intervention group
Group type: COMPARATOR
Intervention: 8Fr guiding catheter
Number of subjects: 160
Study 2645988 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release morphine sulfate tablet (MS Contin) given every 12 hours
Number of subjects: 17
Study 2645988 — intervention group
Group type: COMPARATOR
Intervention: Oral morphine sulfate solution (MSS) given every 4 hours
Number of subjects: 17
Study 31881407 — intervention group
Group type: EXPERIMENTAL
Intervention: BHC (Better Health Choices) - an 8-session telephone delivered coaching intervention
Number of subjects: 43
Study 31881407 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control Condition)
Number of subjects: 43
Study 31291811 — intervention group
Group type: EXPERIMENTAL
Intervention: PCNL under local infiltration anesthesia (PCNL-LIA)
Number of subjects: 36
Study 31291811 — intervention group
Group type: COMPARATOR
Intervention: PCNL under general anesthesia (PCNL-GA)
Number of subjects: 36
Study 31291811 — intervention group
Group type: EXPERIMENTAL
Intervention: PCNL-LIA
Number of subjects: 36
Study 31291811 — intervention group
Group type: COMPARATOR
Intervention: PCNL-GA
Number of subjects: 36
Study 29156152 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich supplements
Number of subjects: 110
Study 29156152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 25398704 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge (discharge ≤3 days)
Number of subjects: 215
Study 25398704 — intervention group
Group type: COMPARATOR
Intervention: Usual care (routine discharge)
Number of subjects: 215
Study 23141686 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT) applied from the first postoperative day (POD) to the seventh POD.
Number of subjects: 6